T. Lin

Flavopiridol: where do we stand in chronic lymphocytic leukemia?

P. Porcu, T. Lin, 2004, Leukemia.

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

J. Byrd, T. Lin, D. Young, 2006, Leukemia.

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.

J. Byrd, B. Cheson, Sin-Ho Jung, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

M. Grever, J. Byrd, I. Flinn, 2005, Leukemia.

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

M. Dyer, R. Foà, K. Rai, 2009, Leukemia.

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

J. Byrd, R. Baiocchi, L. Andritsos, 2007, Oncogene.

Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL).

M. Grever, J. Byrd, B. Rovin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CLL-Cell Proliferation Measured by In Vivo Deuterium Labeling in Early Stage Patients and Correlation with Other Prognostic Markers.

Andrew W. Greaves, L. Rassenti, T. Kipps, 2007 .

Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results.

M. Grever, J. Byrd, R. Baiocchi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epigallocatechin gallate (EGCG), influences a murine WEHI-3 leukemia model in vivo through enhancing phagocytosis of macrophages and populations of T- and B-cells.

Jing-Gung Chung, T. Lin, Jo-Hua Chiang, 2013, In vivo.